← Greenwich LifeSciences, Inc. (GLSI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Greenwich LifeSciences, Inc. (GLSI)
Pharmaceutical Preparations · market cap $273M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Greenwich LifeSciences (GLSI) is a small-cap clinical-stage pharmaceutical company with a market cap of ~$273M and roughly $10.5M in cash (~6.7 months runway). Its lead asset, GLSI-100, is in Phase 3 for breast cancer with a pivotal readout estimated around December 2025, making this a binary event-driven situation ahead of a funding cliff.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GLSI-100 | Phase 3 | Breast Cancer |
| GC1102 50,000 IU | Phase 2 | Hepatitis B Infection |
| CBD | Phase 2 | Diabetic Neuropathies |
| GC3114 | Phase 2 | Influenza, Human |
| GC3110A | Phase 3 | Influenza |
| GC3102C | Phase 3 | Prophylaxis Against Influenza |
| Adjuvanted influenza A(H1N1) vaccine | Phase 3 | Influenza Infection |
| GHB16L2 | Phase 2 | Influenza, Human |
| Hunterase | Phase 3 | Hunter Syndrome |
| Tetanus and Diphtheria(Td vaccine) | Phase 3 | Bacterial Infections |
| GHB11L1 | Phase 2 | Influenza, Human |
| Human immunoglobulin intravenous | Phase 3 | Immune Thrombocytopenia |
| Quadrivalent cell-culture based influenza vaccin | Phase 2 | Influenza |
| GC3110A(Quadrivalent) | Phase 3 | Influenza |
| GC1107 | Phase 3 | Bacterial Infections |
| Quadrivalent influenza vaccine | Phase 2 | Influenza |
| GC5107 | Phase 3 | Immunologic Deficiency Syndromes |
| Step 1 | Phase 2 | Influenza |
| Varicella Vaccine | Phase 3 | Healthy Children |
| MG1109 | Phase 3 | Influenza |
Price & technical context
3-month
-15.7%
6-month
-24.5%
12-month
+70.4%
52-wk range
$7.85–$33.56
vs 50-day MA
+6.3%
vs 200-day MA
-21.3%
Realized vol
102.3%
Max drawdown
-61.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GLSI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.